Search Browse Earnings

Allogene Therapeutics, Inc. — SlamSEC

Allogene Therapeutics, Inc.

Nasdaq:ALLO

Biological Products, (No Diagnostic Substances)·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$22,000

-76.8% YoY

FY 2025

Adj. EBITDA

-$259.6M

-1179818.2% margin

FY 2025

Net Income

-$257.6M

-1170863.6% margin

FY 2025

EPS (Diluted)

-$1.32

FY 2025

Stock Price

$2.23

-1.5%

2026-03-19

52W Range

$0.86 – $2.80

P/E Ratio

-1.7x

Market Cap

$544.8M

Cash

$75.2M

FY 2025

Total Debt

—

Net Cash

$75.2M

FY 2025

Enterprise Value

$469.6M

Debt / EBITDA

0.3x

FY 2025

EV / EBITDA

-1.8x

Employees

—

CEO

Chang David D

CFO

Parker Geoffrey M.